뒤로
HOOKIPA Pharma Inc (HOOK) 수입
HOOK 주가 차트
HOOK 수입
HOOKIPA Pharma Inc
$1.09
3.8%
$0.04
종가: Mar 23, 16:00:00 GMT-4
$1.09
0%
$0
애프터마켓: Mar 23, 20:00:00 GMT-4
최신 수익 결과: Q1 '25
보고됨: 2025-05-15
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
HOOK의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
HOOKIPA Pharma Inc HOOK의 지난 분기 매출 실적은 어땠나요?
HOOKIPA Pharma Inc의 매출 추정치는 얼마인가요?
HOOKIPA Pharma Inc의 수익 품질 점수는 얼마인가요?
HOOKIPA Pharma Inc는 언제 수익을 보고하나요?
HOOKIPA Pharma Inc의 예상 수익은 얼마인가요?
HOOKIPA Pharma Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$1.05
시가
$1.01
일일 범위
$1.01 - $1.09
52주 범위
$0.721 - $1.76
거래량
3.6K
평균 거래량
17.9K
배당수익률
--
EPS(TTM)
-5.85
시가총액
$13.4M
HOOK란 무엇인가요?
HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The company is headquartered in New York City, New York and currently employs 82 full-time employees. The company went IPO on 2019-04-18. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. Its two primary programs include HB-700 and Eseba-vec. HB-700 is a multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Eseba-vec is an investigational immunotherapeutic agent in clinical development for the treatment of HPV16+ head and neck cancers.